reviewTop 1% cited
Targeting the RAF–MEK–ERK pathway in cancer therapy
Cancer Letters · 2009 · Vol. 283(2) · pp. 125–134
Clara MontagutJeff Settleman✉(Harvard University)
Melanoma and MAPK PathwaysCancer Mechanisms and TherapyMultiple Myeloma Research and TreatmentsKinaseMAPK/ERK pathwayCancer researchTyrosine kinaseReceptor tyrosine kinaseSignal transductionMedicineBiologyPharmacologyCell biology
MeSH terms
AnimalsAntineoplastic AgentsClinical Trials as TopicHumansNeoplasmsProto-Oncogene Proteins c-rafMAP Kinase Kinase KinasesMAP Kinase Signaling SystemProtein Kinase InhibitorsExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins B-raf
Funding
- Pfizer
Citations
483
FWCI
18.69
field-weighted impact
References
86
Percentile
100%
vs. same field & year
Citations per year
Cited by
References
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Oncogene · 2007 · 2,782 citations
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
British Journal of Cancer · 2006 · 634 citations
The Hallmarks of Cancer
Cell · 2000 · 28,385 citations
Mitogen-activated protein kinase pathways
Current Opinion in Cell Biology · 1997 · 2,492 citations
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
The Journal of Clinical Endocrinology & Metabolism · 2003 · 1,053 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.